Q2 Compliance Crossroads: DEA's MAT Overhaul, DOJ's Broadened Kickback Focus, and Persistent Fraud Enforcement

2026-06-14

This week's compliance digest unveils critical shifts impacting healthcare providers nationally. From the DEA's transformative changes to medication-assisted treatment prescribing and new training mandates for all controlled substance prescribers, to the DOJ's intensified focus on kickbacks and fraud that extends beyond traditional healthcare, the regulatory landscape demands immediate attention. We dissect these developments, offering actionable insights for telehealth operators, national practices, and compliance officers alike.

The regulatory currents in healthcare are powerful and swift, demanding constant vigilance from every practice, platform, and provider. This past week has seen a series of pivotal developments from federal agencies that underscore both the evolving demands of patient care and the unwavering commitment to combating fraud and abuse. From a landmark DEA rule dramatically reshaping controlled substance prescribing to the Department of Justice's (DOJ) expansive reach in prosecuting kickback schemes, these updates are not mere administrative adjustments; they are fundamental shifts that necessitate immediate re-evaluation of compliance strategies across the healthcare spectrum.

> For more on this topic, see our analysis: [DEA's MAT Overhaul and DOJ's Fraud Crackdown: Navigating the Evolving Compliance Imperative](/blog/dea-mat-overhaul-doj-fraud-crackdown-compliance).

For leaders navigating the complexities of telehealth, the expansion of multi-state brick-and-mortar operations, or the specialized compliance needs of medspas, dental, and chiropractic practices, understanding these shifts is paramount. Non-compliance is no longer a theoretical risk but an imminent threat carrying severe financial and reputational penalties. TrueEval remains committed to distilling these intricate developments into clear, actionable intelligence, positioning your organization to thrive within a dynamic regulatory environment.

> For more on this topic, see our analysis: [DEA's MAT Overhaul and DOJ's Fraud Crackdown: Navigating the Evolving Compliance Imperative](/blog/dea-mat-overhaul-doj-fraud-crackdown-compliance).

DEA Overhauls Controlled Substance Prescribing: The End of DATA-Waivers and a New Universal Training Mandate

One of the most significant regulatory changes to emerge recently comes from the Drug Enforcement Administration (DEA), which has finalized a rule with far-reaching implications for controlled substance prescribers nationwide. This rule, implementing provisions from the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (SUPPORT Act) and the Restoring Hope for Mental Health and Well-Being Act of 2022, represents a seismic shift in how Medication-Assisted Treatment (MAT) for Opioid Use Disorder (OUD) is approached.

The most prominent change is the elimination of the DATA-waiver program, often referred to as the 'X-waiver.' For years, this waiver was a prerequisite for practitioners prescribing buprenorphine for OUD, creating an administrative barrier that limited access to a critical treatment modality. Its removal is intended to expand the pool of prescribers and, consequently, improve patient access to MAT.

However, the elimination of the DATA-waiver does not signal a relaxation of all oversight. Instead, it introduces a **new, one-time training requirement that applies to *all* practitioners who prescribe controlled substances**. This is a critical detail that many may overlook. While the barrier to buprenorphine prescribing has been removed, a new, broader compliance obligation has been established. The training requirement mandates at least eight hours of training on treating and managing patients with OUD and/or other substance use disorders. This applies to a vast array of healthcare professionals, including physicians, physician assistants, nurse practitioners, and other authorized prescribers across specialties, from primary care to specialty practices, and notably, those operating within telehealth platforms.

Furthermore, the final rule codifies provisions allowing pharmacies to deliver certain controlled substances directly to a practitioner's registered location for maintenance or detoxification treatment. This can streamline the dispensing process for MAT programs, offering logistical benefits for practices and improving patient access to medication.

Implications for Your Practice:

Telehealth Platforms: The removal of the DATA-waiver could significantly expand the capacity of telehealth providers to offer MAT, addressing a critical need, especially in underserved areas. However, your clinicians must immediately assess their compliance with the *new universal training requirement*. Ensure all prescribers of *any* controlled substance, not just buprenorphine, complete this one-time training. Failure to do so could jeopardize DEA registration and state licensure.
Medspas, Dental, and Chiropractic Practices: While perhaps not directly involved in OUD treatment, your practitioners who prescribe even Schedule V controlled substances for pain management, anxiety, or other conditions are now subject to this new one-time training. This is a broad mandate and requires a comprehensive review of your prescribing staff's qualifications and training records. Ignoring this universal requirement is a significant compliance risk.
Compliance Officers: This rule demands an immediate update to your internal training protocols and a comprehensive audit of all controlled substance prescribers within your organization to verify completion of the new eight-hour training. Establish clear documentation policies for this training.

DOJ's Broad Net: Combating Kickbacks Beyond Traditional Healthcare Fraud

The Department of Justice (DOJ) continues its relentless pursuit of fraud and kickbacks, extending its reach into areas that serve as critical reminders for the healthcare sector. Two recent enforcement actions highlight this unwavering commitment, demonstrating that the principles of fair competition and integrity in government funding apply broadly, with direct implications for healthcare providers.

Procurement Integrity: A Warning Across All Government Funds

While not a healthcare-specific case, the guilty plea of David Duggin, a former U.S. Intelligence Community contractor, for soliciting and accepting over $510,000 in illegal kickbacks, sends a powerful signal. This case underscores the DOJ's robust enforcement against individuals who corrupt government procurement processes for personal gain. Crucially, the DOJ's Procurement Collusion Strike Force (PCSF), which led this investigation, explicitly targets fraudulent schemes impacting 'government procurement, grant and program funding at all levels of government — federal, state and local.'

Why This Matters to Healthcare:

Many healthcare businesses, including telehealth brands, medspas, dental practices, and chiropractic offices, participate in federal and state programs involving government funds. This includes Medicare, Medicaid, federal grants, state contracts for public health services, or even local government funding initiatives. The PCSF's broad mandate means that any healthcare entity receiving *any* form of government funding or contracting with government agencies must maintain stringent compliance programs.

Anti-Kickback Statute (AKS) and False Claims Act (FCA) Intersections: The principles highlighted in the Duggin case — the prohibition against illegal financial inducements and the severe penalties for corruption — are directly applicable to healthcare under the AKS and FCA. Any arrangements involving referrals, the procurement of services or goods, or the use of government funds must be transparent, commercially reasonable, and free from direct or indirect kickbacks. The DOJ's focus on 'procurement integrity' should prompt healthcare organizations to re-examine all vendor relationships, referral arrangements, and consulting agreements for any potential kickback implications, especially if government funds are involved.
Scrutiny of Vendor Relationships: Ensure your relationships with suppliers, third-party administrators, marketing firms, and other vendors are structured to avoid any appearance of inducements tied to referrals or the volume/value of business generated, particularly when public payors are involved. Due diligence on all business partners is paramount.

Persistent Healthcare Fraud: The Enduring Threat

Closer to home, the federal sentencing of Sean Rondeau, an Illinois chiropractor, to federal prison for healthcare, mail, and wire fraud, serves as a stark reminder of the enduring threat of direct healthcare fraud. Rondeau was convicted for defrauding health insurance companies of over a quarter-million dollars through fraudulent billing and misrepresentation.

Universal Lessons for All Healthcare Providers:

This case, while involving a chiropractor, resonates across all healthcare sectors. The Department of Justice actively pursues cases involving fraudulent billing, misrepresentation of services, upcoding, and any schemes designed to unlawfully enrich providers at the expense of insurance payers, whether public or private. This includes:

Telehealth Providers: Misrepresenting the nature or duration of virtual visits, billing for services not rendered, or improper coding for remote patient monitoring can lead to severe federal charges.
Medspas: Billing for cosmetic procedures as medically necessary, unbundling services, or misrepresenting provider credentials for reimbursement are significant risks.
Dental Practices: Fraudulent billing practices, such as performing unnecessary procedures, upcoding, or billing for services not actually provided, face intense scrutiny.
Chiropractic Offices: As the Rondeau case illustrates, misrepresenting treatment necessity, duration, or outcomes to inflate claims is a direct path to federal prosecution.

Actionable Insight: The core defense against such charges lies in a robust compliance program that emphasizes diligent record-keeping, accurate coding, and comprehensive staff training on billing and claims submission practices. Every service rendered and every claim submitted must be scrupulously documented and reflect actual, medically necessary care. The consequences of failure are severe: federal imprisonment, substantial financial penalties, and professional licensure revocation.

What This Means For Your Practice: Proactive Compliance as Your Best Defense

The past week's developments paint a clear picture: healthcare compliance is not static. It is a dynamic, expansive field where regulatory changes and enforcement actions continually redefine the boundaries of permissible conduct. For healthcare executives, founders, and compliance officers, the message is unequivocal: proactive, adaptive compliance is no longer a choice; it is an existential necessity.

Here are the immediate actionable steps to consider:

1. DEA Training Mandate Audit: Immediately identify all practitioners within your organization who prescribe *any* controlled substances. Verify their awareness of and compliance with the new, one-time eight-hour training requirement. Implement a clear tracking and documentation system for this training completion. Update your onboarding and ongoing training curricula accordingly. 2. Kickback Risk Assessment (Broadened Scope): Review *all* business arrangements, vendor contracts, marketing agreements, and referral sources, particularly those involving any government funding (Medicare, Medicaid, state grants, local contracts). Ensure these arrangements are transparent, documented, commercially reasonable, and devoid of any direct or indirect inducements that could be construed as kickbacks. Pay special attention to the PCSF's broad interpretation of government funds. 3. Billing and Coding Integrity Re-evaluation: Reinforce internal controls for billing and coding accuracy. Conduct regular internal audits to identify and rectify any patterns of potential misrepresentation, upcoding, or billing for services not rendered. Emphasize comprehensive, accurate documentation to support every claim. 4. Staff Education Refresh: Prioritize ongoing education for all staff, from front-desk personnel to clinical providers, on the latest regulatory changes, fraud detection, and ethical conduct. A well-informed team is your first line of defense against compliance breaches. 5. Leverage Technology for Compliance: Modern healthcare demands modern compliance solutions. Implement systems that can track licensure, DEA registrations, training completion, and robust audit trails for patient encounters and billing. TrueEval's infrastructure is specifically designed to manage these complexities, ensuring your practice remains agile and compliant.

The regulatory landscape is converging – greater flexibility in one area (like MAT prescribing) is often balanced by increased scrutiny and new universal requirements in others. The DOJ's enforcement arm is reaching further, linking seemingly disparate cases to a core message of integrity in *all* interactions involving government funds. Staying ahead requires not just awareness, but a commitment to building a culture of compliance that is embedded in every operational facet of your practice. The cost of non-compliance is simply too high to ignore.